These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23146417)

  • 1. Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.
    Vadot L; Boulin M; Malbranche C; Guiu B; Aho S; Musat A; Pernot C; Guignard MH; Hillon P; Fagnoni P
    Diagn Interv Imaging; 2013 Jan; 94(1):53-9. PubMed ID: 23146417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].
    Malbranche C; Boulin M; Guiu B; Pernot C; Cercueil JP; Serge Aho L; Musat A; Bedenne L; Hillon P; Guignard MH; Fagnoni P
    Bull Cancer; 2011 Jun; 98(6):671-8. PubMed ID: 21642049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
    Vadot L; Boulin M; Guiu B; Aho LS; Vourc'h M; Musat A; Hillon P; Lepage C; Guignard MH; Fagnoni P
    J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study comparing the cost-effectiveness of conventional and drug-eluting transarterial chemoembolisation (cTACE and DEB-TACE) for the treatment of hepatocellular carcinoma in an Australian public hospital.
    Clements W; Chenoweth A; Phipps B; Mozo L; Bolger M; Morphett L; Phan T; Koukounaras J; Lukies MW
    J Med Imaging Radiat Oncol; 2024 Sep; 68(6):714-720. PubMed ID: 38985987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
    Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
    J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medico-economic study of the management of hepatocellular carcinoma by chemo-embolization.
    Clouet J; Audureau D; Lefranc B; Maillard N; Guilé R; Frampas E; Perret C; Grimandi G
    Diagn Interv Imaging; 2014 Apr; 95(4):427-34. PubMed ID: 24231346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
    Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
    J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
    Varela M; Real MI; Burrel M; Forner A; Sala M; Brunet M; Ayuso C; Castells L; Montañá X; Llovet JM; Bruix J
    J Hepatol; 2007 Mar; 46(3):474-81. PubMed ID: 17239480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Chen P; Yuan P; Chen B; Sun J; Shen H; Qian Y
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):75-85. PubMed ID: 27350573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
    Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma.
    Asayama Y; Okamoto D; Ushijima Y; Nishie A; Ishigami K; Takayama Y; Fujita N; Honda H
    Clin Radiol; 2017 Sep; 72(9):780-785. PubMed ID: 28442142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.